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The incidence of cervical cancer in Malawi is the highest in the world and projected to increase in the absence of interven-
tions. Although government policy supports screening using visual inspection with acetic acid (VIA), screening provision is lim-
ited due to lack of infrastructure, trained personnel, and the cost and availability of gas for cryotherapy. Recently, thermo-
coagulation has been acknowledged as a safe and acceptable procedure suitable for low-resource settings. We introduced
thermo-coagulation for treatment of VIA-positive lesions as an alternative to cryotherapy within a cervical screening service
based on VIA, coupled with appropriate, sustainable pathways of care for women with high-grade lesions and cancers.
Detailed planning was undertaken for VIA clinics, and approvals were obtained from the Ministry of Health, Regional and Vil-
lage Chiefs. Educational resources were developed. Thermo-coagulators were introduced into hospital and health centre set-
tings, with theoretical and practical training in safe use and maintenance of equipment. A total of 7,088 previously
unscreened women attended VIA clinics between October 2013 and March 2015. Screening clinics were held daily in the hos-
pital and weekly in the health centres. Overall, VIA positivity was 6.1%. Almost 90% received same day treatment in the hos-
pital setting, and 3- to 6-month cure rates of more than 90% are observed. Thermo-coagulation proved feasible and
acceptable in this setting. Effective implementation requires comprehensive training and provider support, ongoing compe-
tency assessment, quality assurance and improvement audit. Thermo-coagulation offers an effective alternative to cryotherapy
and encouraged VIA screening of many more women.
Cervical cancer is the commonest cancer and the leading cause
of cancer deaths among women in low- and middle-income
countries (LMIC).1 In 2008, the World Health Organisation
(WHO) reported >530,000 new cases and 275,000 deaths from
cervical cancers worldwide, with more than 90% of cases from
developing countries.2 In the WHO African region, 75,000 new
cases were recorded with more than 50,000 deaths.2 Malawi was
reported to have the highest rate of cervical cancer in the world
in 2012 with a world age-standardised rate of 75.9 per 100,000,3
and high rates of cervical cancer are reported among human
immunodeficiency virus (HIV)-infected women.4
The Malawian Ministry of Health Strategic Plan includes
provision of cervical screening using Visual Inspection with
Acetic Acid (VIA).5 Treatment of early lesions with cryother-
apy is included in national policy, in line with the WHO’s
Comprehensive Cervical Cancer Control ‘A Guide to Essen-
tial Practice’.6 WHO recommends cryotherapy or loop elec-
trosurgical excision procedure for larger lesions for the
majority of women who screen positive for cervical pre-
cancer in ‘screen-and-treat’ programmes in LMIC.6,7
While setting up a screen-and-treat programme of cervical
screening in Central Region, Malawi, in 2013, it very quickly
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became evident that lack of availability of gas for cryotherapy
and its prohibitive cost meant there was a need to urgently
consider an alternative treatment modality. The evidence
regarding the effectiveness of thermo-coagulation (also called
cold coagulation), an ablative method for treatment of cervical
intraepithelial neoplasia (CIN), led to our consideration of its
use in Malawi. Thermo-coagulation has a number of attractive
features making it suitable for use in LMICs: the equipment is
small, portable and durable, destroys abnormal cells at 100–
1208C in brief treatment applications using minimal electricity
and allows punch biopsies to be taken in the screening clinic
for investigation of potentially cancerous lesions. The PATH
review of treatment modalities for precancerous cervical
lesions considers there to be evidence to support either no or
local anaesthesia for thermo-coagulation in LMIC settings.8
The absence of pain in the initial stages of cervical cancer, the
cost of healthcare, the distance to health facilities covered usu-
ally by foot and the common experience of abnormal bleeding
during reproductive years means that many Malawian women
do not seek timely medical help. It is therefore important to
provide treatment at the same time as screening, as the screen-
ing visit may be the only chance for intervention.
Cumulative evidence over the last three decades has dem-
onstrated the effectiveness of thermo-coagulation treat-
ment.9–11 A recent systematic review and meta-analysis of
effectiveness of thermo-coagulation summarised data from 13
studies, reporting on the analyses of proportion of patients
cured, with results stratified by lesion grade and study
region.12 Among 4,569 patients, summary proportions cured
for CIN1 and CIN2-3 disease were 96 and 95%, respectively.
However, few of the included studies were from low-income
settings. Recent studies from India are beginning to provide
such evidence.13,14 Preliminary findings indicated that use of
thermo-coagulation for treatment of lesions suggestive of
CIN among HIV-infected women in India was well tolerated
without anaesthesia and was safe for delivery in out-patient
settings, with 6-month cure rates of more than 80%.13 The
overtreatment rate of 32% of women who had no histological
evidence of CIN was similar to that of unnecessary treatment
following ablative treatment using cryotherapy in ‘see-and-
treat’ settings.15
Apart from the evidence from India there is as yet limited
published data for effective delivery of thermo-coagulation in
screening programmes in LMIC, with none from
Sub-Saharan African countries. Crucially, the 2014 2nd
Edition WHO CCCC Guidance7 does not mention thermo-
coagulation, a major impediment to adoption of this technol-
ogy in LMIC. This article describes the use of thermo-
coagulation within a screen-and-treat programme in Malawi.
Material and Methods
Settings
CCAP Nkhoma Hospital serves the Lilongwe and Dedza Dis-
tricts of Central Malawi, with a population of some 375,000.16 A
service-level agreement with the Malawi Government enables
provision of free care for mothers and children aged below 5
years. Together with the emphasis on strengthening reproduc-
tive health services,17 this has resulted in a dramatic reduction
in maternal mortality in the area (from 1,518/100,000 live births
in 2008 to 170/100,000 in 2014; Nkhoma Hospital audit, R. Ter
Haar). The first two health centres to link into the programme
were Kasina and Nathenje Health Centres.
Cervical screening in Nkhoma
A VIA service has been available in Nkhoma since 2005. In
the 18 months prior to this project, a total of 618 women
were screened, with just more than 6% VIA positivity, with a
similar number of suspected cancers. There is, however, a lack
of detail on treatment given and clinical outcomes. A service
improvement was therefore planned which sought to redesign
all aspects of the screen and treat programme. Initial steps
included obtaining support and approvals from the Malawian
Ministry of Health, Regional and Village Chiefs and sensitisa-
tion in hospital, health centre and village settings.
The Nkhoma Cervical Cancer Screening Programme (CCSP)
has been integrated within an existing Reproductive Health
Unit, allowing broadening of staff skills and ensuring consis-
tency of messages to women. Attendance at the Malawian Min-
istry of Health VIA course is a prerequisite for all providers and
is supplemented by additional training in VIA interpretation
and treatment using thermo-coagulation at Nkhoma Hospital.
Full details of the Nkhoma hub and spokes model of cervical
cancer screening and supporting pathways of treatment will be
published elsewhere (manuscript in preparation).
Daily screening and referral clinics were set up in Nkhoma
Hospital, and within 3 months, weekly screening clinics were
operating at Kasina and Nathenje Health Centres.
Women who come to screening clinics first attend a 30-
to 40-minute verbal educational and interactive group session
in the local Chichewa language.
Provision of VIA is in accordance with WHO Guidance,7
Malawian Ministry of Health policy,5 and draws on
JHPIEGO materials.18 Women are seen in a private/curtained
area and 5% acetic acid applied to the cervix for 1 minute.
What’s new?
Malawi has the highest incidence rates for cervical cancer worldwide, and a “screen-and-treat” program is in place to identify
and treat precancerous lesions. Conventional cryotherapy is challenging as gas supply is inconsistent, cylinders are difficult
to transport and running costs are high. Here, the authors introduce thermo-coagulation as a treatment alternative, which
proved feasible and acceptable in this resource-poor setting and could increase the number of women receiving timely treat-
ment for precancerous lesions in low- and middle-income countries.
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VIA outcomes are documented as ‘negative’ (no aceto-white
areas observed); ‘positive’ (well-defined areas of aceto-white
covering <75% of transformation zone with the squamo-
columnar junction fully visible and no evidence of entering
the endo-cervical canal) and ‘suspicious lesion, biopsy
required’ and ‘advanced cancer’. Women who are VIA-
negative are asked to return at 3 years (or 1 year if HIV-posi-
tive) for routine screening.
Women who are considered VIA-positive are offered
immediate treatment with thermo-coagulation rather than
cryotherapy. The heated probe is applied to the cervix for 30
seconds. Applications are repeated on all areas of the cervix
which need treatment. No local anaesthetic is offered, con-
sistent with the approach taken in other LMIC settings.13,14
Thermo-coagulation is not provided if there is any evidence
of glandular neoplasia or cervical cancer or if the woman is
pregnant. Women from all health centres for whom a suspi-
cion of cancer is recorded are referred to Nkhoma for punch
biopsy to confirm the diagnosis.
Women are directed to return for a follow-up review at
3–6 months and again at 1 year. The first visit was set at 3
months initially to meet Malawian guidelines for treatment
with cryotherapy. Following discussion with senior Malawian
service providers, this was changed after the first year of the
programme to 6 months to be in line with guidance from
users of thermo-coagulation, recognising that 3 months was
too early for complete healing and could lead to false inter-
pretation of faint aceto-white areas.
Pathways of care are in place for all women. Women
from whom a punch biopsy has been taken return within 1
month for biopsy results and discussion of clinical manage-
ment pathways, including surgical options or palliative care.
Interviews with providers
Six interviews were carried out with providers at Nkhoma
Hospital, with consent from senior management and from
the providers themselves for their anonymised views to be
shared. All providers are involved in screening provision at
Nkhoma Hospital and at rural health centres; three had
experience of using both thermo-coagulation and cryotherapy
as a treatment modality. Interviews were carried out in April
2015 using a brief questionnaire asking about provider expe-
rience and perspectives; responses were recorded verbatim.
Data collection and analysis
To date, 18 months data from Nkhoma Hospital (from October
2013 to end of March 2015) and 11 months data from Kasina
HC and Nathenje HC (from May 2014 to end of March 2015)
have been analysed. Data were recorded in standard Malawian
Ministry of Health VIA screening registers, and then entered
into an Excel database, using numerically coded menus to allow
for easy analysis and data checking. Descriptive statistics were
used to summarise outputs of interest.
Results
Screening attenders
Between October 2013 and March 2015, a total of 7,910 women
were screened by VIA. This included 5,424 women seen at daily
clinics in Nkhoma Hospital, and 1,472 and 1,014 women seen
at Kasina and Nathenje, respectively. The vast majority of
women (7088; 89.6%) had never attended for cervical screening
before. Programme descriptors for those attending screening
for the first time are presented in Table 1. Amongst first attend-
ers, 381 were known to be HIV-positive (5.4%).
Age distribution
The age distribution was similar at each site, with peak attend-
ance between ages 20 and 39 years in all three centres. Percent-
age age distribution for those aged 20–29 years ranged from
24% Nathenje to 31.7% Kasina; conversely, the % aged 30–39
years in Nathenje was 37% compared to 28% in Kasina. A size-
able proportion of women who attended were aged more than
60 years (6.7%), whereas only 1.5% were aged below 20 years;
however, 24 women did not know their age.
Attendance by site
Quarterly numbers by site are presented in Figure 1 and
show a steep rise in activity in the first quarter after sensitisa-
tion, followed by a reduction. As the Health Centre clinics
became more experienced and extended their capacity, the
number of women attending locally increased, whereas the
number attending Nkhoma Hospital reduced.
Table 1. Characteristics of women attending cervical screening for the first time in Nkhoma Hospital and in Kasina and Nathenje Health
Centres, Central Malawi
Location
Number
of first
attenders
% of total
attendance
Age
range
(years)
Marital
status
HIV status
in first
attenders
% never
married
HIV1
(ART)
HIV1
(no ART)
% HIV1 HIV2 % HIV2 HIV
unknown
% HIV
status
unknown
Nkhoma 4,730 87.2 16–86 1.8 257 38 6.2 1,963 41.5 2,472 52.3%
Kasina 1,393 94.6 16–82 3.2 35 14 3.5 614 44.1 730 52.4%
Nathenje 965 94.9 17–74 3.0 24 14 3.9 494 51.2 433 44.9%
Total 7,088 89.4 16–86 2.2 315 66 5.4 3,069 43.3 3,632 51.3%
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VIA positivity
The number and percent of women who were considered
VIA-positive reduced over time as experience to distinguish
early/low-grade lesions from non-specific changes increased.
This is summarised in Table 2 where the percent of VIA-
positive women overall who were treated on the same day
was 84%, was lower in the Health Centres (72.3%) and
reached 89% in Nkhoma Hospital.
Additional via outcomes
Further clinical outcomes are presented in Table 3 and show 1.4%
of women had suspicious or advanced cancers. When VIA out-
comes are stratified by age (Fig. 2), it is clear that most early and
treatable lesions occur in age groups 20–39 years, whereas cancer-
ous lesions are largely in the age groups 30–59 years. Of the 22
women who needed radical hysterectomy in the 18 months under
discussion, eight (36%) were aged 60 years or above.
VIA results by HIV status
Overall, 5.3% (n5 381) of first attenders were known to be
HIV-positive, most of them receiving anti-retroviral therapy
(ART) on a regular basis. Forty HIV-infected women were
also VIA-positive (10.4%; 33 on ART and 7 not on ART).
This compares with a VIA positivity rate of 6.6% known to
be HIV-negative or 5.1%% in the overall population regard-
less of HIV status (Table 4).
Clinical follow-up
Between Nkhoma hospital and the two health centres, more
than 63% of women have returned for a first follow-up visit,
mostly at around 3 months after treatment. More than 90%
of cervices appeared well healed at this stage (Table 5). Seven
women required further thermo-coagulation treatment, repre-
senting a 94.0% cure rate at first follow-up (220/234); assess-
ment of outcome for a further seven women could not be
made on the day of visit for a variety of reasons (e.g.,
thermo-coagulation scarring still evident, pregnancy and
menstruation). When analysed by HIV status, no treatment
failures were observed in HIV-positive women in our treated
Figure 1. Quarterly first attendance by clinic site in Central Malawi.
Table 2. Outcomes of ‘screen-and-treat’ programme in Central Malawi by site and age
Clinic location
First
attenders
Number of
patients with
VIA-positive %
Number of
patients treated
same day %
Number of
patients returned
in <1 month for
treatment Total treated (%)
Nkhoma 4,730 299 6.3 267 89 9 276 (92.3%)
Kasina 1,393 85 6.2 65 68 8 73 (86%)
Nathenje 965 45 4.7 29 64.4 3 32 (71.1%)
Total 7,088 429 6.1 361 84.1 20 381 (88.8%)
Table 3. Outcomes of ‘screen-and-treat’ programme in Central
Malawi by clinical assessment and age
VIA result in first
attenders Nkhoma Kasina Nathenje Total
VIA1 299 85 45 429
VIA2 4,264 1,287 907 6,458
Suspicious cancer 58 14 6 78 (1.1%)
Advanced cancer 20 2 0 22 (0.3%)
Other gynaecological 39 5 7 51
Unknown 50 0 0 50
Total 4,730 1,393 965 7,088
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cohort (n5 12), compared to 2/94 known HIV-negative, and
4/89 where HIV status was not known.
To date, 61 women have also returned for 1-year follow-up:
nine (14.7%) required further treatment and were considered
treatment failures: the number attending 1-year review visits will
increase over time. Treatment failure occurred in one of 11
HIV-positive women, compared to five of 26 HIV-negative
women and three of 24 women whose HIV status was
unknown.
Provider perspectives
Local providers reported satisfaction with comprehensive
training in use of thermo-coagulation, perceived acceptability
of treatment to women, satisfaction expressed by women
regarding explanation of procedure and ease of practical
setup. Almost no pain was reported to the providers when
women received treatment. Providers who had experience of
use of both thermo-coagulation and cryotherapy reported
shorter time taken for treatment with thermo-coagulation,
perceived greater acceptability to women and anecdotally
fewer treatment sequelae.
Discussion
Summary of findings
In our population, 6.1% of screened women were VIA-
positive, of whom overall 84% received same-day treatment
with thermo-coagulation. About 89% of women attending the
daily screening clinics in Nkhoma Hospital received same-
day treatment, compared to 68 and 64% in the two health
centres. These lower rates demonstrate the complexity of
Figure 2. Screening outcomes (VIA-positive and suspicious cancers, by age) across three health centres in Central Malawi.
Table 4. VIA outcomes in a ‘screen-and-treat’ programme in Central Malawi according to HIV status
VIA result
HIV-positive
on ART
HIV-positive
not on ART HIV-negative
HIV status
unknown Total
VIA1 33 7 203 186 429
VIA2 316 65 3,070 3,637 7,088
% VIA-positive 10.4 10.8 6.6 5.1 6.1
Table 5. Outcomes of first follow-up visit for 234 women attending VIA screening clinics in Central Malawi
Number of patients
with VIA-positive
Total number of
patients treated
(within 1 month)
Number of patients
returned for first
follow-up
Number of
patients
healed
Number of
patients with
continuing problem
Nkhoma 299 276 195 (73.8%) 182 (93.3%) 6
Kasina 85 73 23 (30.3%) 22 (95.7%) 1
Nathenje 45 32 16 (55.2%) 16 (100%) 0
Total 429 381 234 (63.4%) 220 (94.0%) 7 (3.0%)
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service delivery in settings where thermo- coagulators for
treatment are not always available when required (i.e., may
only be available one clinic in four), and where trained staff
are few or deployed elsewhere. Nevertheless, the success of
the Nkhoma model would suggest that there is an opportu-
nity for expansion to impact significantly on population cov-
erage and treatment of precancerous lesions. By March 2015,
the numbers attending Kasina HC matched the number
attending in Nkhoma Hospital, showing how outreach can
reduce the burden on central resources while at the same
time providing a service closer to home.
Comparisons with the literature
Widespread acceptance with varying rates of VIA positivity
depending on setting are reported in sub-Saharan Africa.19–22
Our rates of VIA positivity and suspicious lesions are compa-
rable to those found by others,13,21,23 and the higher rate in
HIV-infected women (11.1% VIA positivity in HIV-positive
women versus; 7.1% HIV-negative) reinforces the importance
of offering cervical screening services to HIV-positive women,
and where appropriate, encouraging women of unknown
HIV status to consider HIV testing. In Malawi, the HIV sta-
tus is unknown if testing has been carried out more than 1
year before, thus accounting for the large number of women
of unknown HIV status (n5 3,637, 51.3%). The majority of
the ‘HIV status unknown’ women were older (48.5% in
women aged below 50 years compared to 64.5% in those
aged above 50 years), which may account for the lower VIA
positivity in this group.
We report on early outcomes of thermo-coagulation as
the treatment modality within our VIA-positive population.
There is now a growing body of evidence supporting the use
of thermo-coagulation within screen-and-treat programmes,
and our interim cure rate (3–6 months post-treatment) of
93.3% in 234 women compares well with preliminary cure
rate with thermo-coagulation of >80% (at 6 months to 1
year) in HIV-positive women in India, 95.7% at 1 year in the
United Kingdom and 96.5% for CIN1/95% for CIN2-3 from
a meta-analysis.10,12,13 It also compares favourably with docu-
mented cure rates from cryotherapy.24 Our preliminary
results at 1-year follow-up from a small number of women
(cure rate of 85%) are incomplete, but reinforce the need for
regular follow-up and re-screening of treated women in
accordance with national guidance. Importantly, cure rates at
both time points did not differ by HIV status.
Others have reported on the experience of VIA-based
“screen and treat” in Malawi. An early demonstration pilot
found VIA positivity rates of 12.4%, but limited ability to
provide same-day treatment.19 There are acknowledged
health system and cultural challenges to delivery of cervical
screening in Malawi,25,26 most pertinently that only one-third
of facilities surveyed recently were able to provide treatment
due to lack of cryotherapy equipment or gas.27 There are also
reports of patient satisfaction28 and examples of successful
integration with existing services.23
The potential for overtreatment in screen-and-treat pro-
grammes with VIA is recognised.7,29 Discrimination of VIA
positive lesions associated with pre-neoplasia from other cer-
vical pathologies including chronic infection requires clinical
skill and experience. The gold-standard confirmation would
be biopsy which is not readily available in most low-resource
settings. A screen-and-treat approach enables treatment on
the same day to be offered to women, critical in many low-
resource settings where patients are less likely to return for
treatment in the absence of symptoms and where travel is
costly and time consuming.12,13 WHO guidance considers the
benefit to outweigh any harm from cryotherapy in VIA-
based screen-and-treat programmes in low-resource settings.7
The same principle applies for treatment with thermo-
coagulation.
Strengths and weaknesses of this study
The Nkhoma CCSP represents a service improvement pro-
gramme rather than a comparison study with other treatment
modalities. This can be seen as both a strength (i.e., real-time
field testing) and a weakness (i.e., no data to compare with
Malawian Ministry of Health and WHO-recommended treat-
ment modality of cryotherapy). We do not have colposcopic
or biopsy confirmation for women who are VIA-positive, as
this is truly a screen-and-treat service delivery approach.
However, comparisons with published results from other
papers suggest similar outcomes (described above). Nonethe-
less, we recognise the importance of ensuring adequate
follow-up of all treated women, and the provision of mes-
sages about symptom recognition and access to relevant
services.
Ensuring women do return for treatment, and/or for
follow-up, is a recognised challenge. Although overall a high
proportion of women (84%) did accept same-day treatment,
some women felt obliged to seek permission from their hus-
band before accepting treatment, in part due to the recom-
mendation of sexual abstinence for 4 weeks post-treatment.
We experienced more than 60% of women returning for first
follow-up (at 3–6 months post-treatment) with only a date
for return recorded in their Health Passport, and to date, 61
women have returned for their 1-year follow-up. This may
be an under-reporting of the true figure due to women
attending follow-up visit at their local health centre rather
than Nkhoma Hospital, where they might be given a new
clinic number. We now record mobile telephone numbers
(where available) and village/territory addresses to increase
the proportion of women returning for their 1-year review
appointment (or within 2 months of the suggested date).
Anecdotal concerns have been raised about the level of
pain associated with thermo-coagulation. However, treatment
with thermo-coagulation was acceptable and well tolerated by
women, as found by others13,30: there is little evidence to sug-
gest greater pain than with cryotherapy, with only one
acknowledgement of pain beyond discomfort noted among
over 200 treated women in our population. We recognise
C
an
ce
r
T
he
ra
py
an
d
P
re
ve
n
ti
on
6 Use of thermo-coagulation in a ‘screen-and-treat’ programme
Int. J. Cancer: 00, 00–00 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
that this low figure is based on provider report, and work is
ongoing to directly capture detailed patient perspectives.
About 91.6% of our screened women were aged between
20 and 59 years, with 52% within the WHO-recommended
screening ages of 30–49 years in LMIC settings.7 We found
high levels of VIA positivity among younger women, but
43.6% of the suspicious cancers were among women older
than 49 years. The Nkhoma cervical cancer prevention pro-
gramme is not a formal screening programme, and the wide
age range reflects the necessity of routine gynaecological
health care among women in an unscreened population.
Implications for practice, policy and research
Practice. Introduction of a screen-and-treat programme
requires initial familiarisation and training, but must also be
accompanied by ongoing support, continuing professional
education and quality assessment of providers. The Nkhoma
programme developed bespoke standard operating procedures
and assessment tools (competence assessment form, also
called Objective Structured Clinical Assessment, OSCA);
other clinical assessment tools are also available.18
Policy. Although WHO 2013 guidance does not include
thermo-coagulation as a treatment modality, there is growing
use of and support for thermo-coagluation in a number of
LMIC settings.12,13,31–33 As evidence accumulates for non-
inferior outcomes for thermo-coagluation pre-cancers com-
pared to other treatment modalities,12,24,34 guidance should
be reviewed and updated. Similarly, health care planners in
LMICs should consider inclusion of thermo-coagulation in
strategic planning for long-term cost-effectiveness and sus-
tainable delivery of screening programmes.
Although we did not include formal cost-effectiveness
analysis, capital outlay for thermo-coagulation indicated that
cost savings can be made after 80 to 90 women have been
treated. Provided sufficient women are screened in the popu-
lation and then the initial cost is recouped within a period of
months, compared to the recurring costs for cryotherapy.
One drawback of thermo-coagulation is that currently
there is only one supplier of suitable instruments34 (WISAP,
Germany): a more competitive market could drive down
price. Battery-operated thermal coagulators are under devel-
opment although it could take until mid-2016 to have a com-
mercially available device.35 Other ablative treatment
modalities are being developed and trialled, such as the Cry-
open (PATH).8
Future research priorities. There is a need for further robust
data collection regarding the use of thermo-coagulation in
sub-Saharan Africa and other LMIC settings, as well as other
programme indicators.36 Comparative studies are not always
possible in resource-constrained settings, but sufficient data
points should be recorded of key indicators to allow out-
comes and should include long-term efficacy through follow-
up of treated women, safety profile (e.g., pregnancy out-
comes), and data on client experience. Future models of
screen-and-treat should explore the use of HPV testing for
potential triage to VIA as recommended by WHO and
others13,37–39: refinement of optimal treatment strategies for
HIV-positive compared to HIV-negative women,37 as well as
investment in effective, cost-effective and acceptable treat-
ment such as thermo-coagulation. There is also a need for
health systems research into how to implement evidence on
screening delivery in practice,40,41 as well as integration with
HIV/ART and reproductive health services.20,23 At Nkhoma
Hospital, HIV testing and counselling is now offered in the
VIA settings, and annual VIA screening is being introduced
as the standard of care for women with HIV attending ART
clinics.
Conclusions. Our study demonstrates that introduction of
thermo-coagulation is feasible and acceptable within this
LMIC setting. The same-day nature of a treatment acceptable
to providers and to patients, the ease of transportation to
rural health centres and the evidence of clinical effectiveness
all argue for more widespread adoption of thermo-
coagulation for sustainable and reliable screening provision
in LMIC as an alternative to cryotherapy.
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